BR112013022052A2 - ligantes antagonísticos de dr3 - Google Patents
ligantes antagonísticos de dr3Info
- Publication number
- BR112013022052A2 BR112013022052A2 BR112013022052A BR112013022052A BR112013022052A2 BR 112013022052 A2 BR112013022052 A2 BR 112013022052A2 BR 112013022052 A BR112013022052 A BR 112013022052A BR 112013022052 A BR112013022052 A BR 112013022052A BR 112013022052 A2 BR112013022052 A2 BR 112013022052A2
- Authority
- BR
- Brazil
- Prior art keywords
- antagonistic ligands
- antagonistic
- treatment
- ligands
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo patente de invenção: "ligantes antagonísticos de dr3". a presente invenção refere-se ao tratamento de doenças infla-matórias. em particular, a presente invenção refere-se a ligantes antagonís-ticos de dr3 úteis para o tratamento de doenças inflamatórias.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11156416 | 2011-03-01 | ||
US201161448827P | 2011-03-03 | 2011-03-03 | |
PCT/EP2012/053539 WO2012117067A1 (en) | 2011-03-01 | 2012-03-01 | Antagonistic dr3 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013022052A2 true BR112013022052A2 (pt) | 2016-11-22 |
Family
ID=44210048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013022052A BR112013022052A2 (pt) | 2011-03-01 | 2012-03-01 | ligantes antagonísticos de dr3 |
Country Status (12)
Country | Link |
---|---|
US (4) | US9737612B2 (pt) |
EP (1) | EP2681237A1 (pt) |
JP (1) | JP6215056B2 (pt) |
KR (1) | KR20140043720A (pt) |
CN (1) | CN103517918A (pt) |
BR (1) | BR112013022052A2 (pt) |
CA (1) | CA2828464A1 (pt) |
IL (1) | IL227535A0 (pt) |
MX (1) | MX2013009859A (pt) |
RU (1) | RU2013141079A (pt) |
WO (1) | WO2012117067A1 (pt) |
ZA (1) | ZA201306110B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150140679A (ko) * | 2013-03-15 | 2015-12-16 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 항원-특이적 b 세포를 확인하고 단리시키고, 원하는 항원에 대한 항체를 생성하기 위한 프로토콜 |
WO2015036553A1 (en) | 2013-09-16 | 2015-03-19 | Novo Nordisk Health Care Ag | Thiol functionalized polymers |
US9416197B2 (en) | 2013-11-01 | 2016-08-16 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease |
KR20160138083A (ko) | 2014-04-04 | 2016-12-02 | 교와 핫꼬 기린 가부시키가이샤 | 감소된 효현 활성을 가진 항-사멸 수용체 3(dr3) 길항성 항체 |
AU2015254818A1 (en) | 2014-04-28 | 2016-11-17 | The National Institute for Biotechnology in the Negev Ltd. | Variants of DR3 and use thereof |
CN110199017A (zh) * | 2017-01-20 | 2019-09-03 | 国立大学法人京都大学 | CD8α+β+细胞毒性T细胞的制备方法 |
EP3860653A1 (en) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
CN111808183B (zh) * | 2020-07-25 | 2022-07-08 | 北京吉尔麦迪生物医药科技有限公司 | 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白 |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
CN116223818B (zh) * | 2023-05-09 | 2023-07-21 | 四川大学华西医院 | Dr3蛋白检测试剂在制备筛查aecopd的试剂盒的用途及筛查aecopd的试剂盒 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3946256B2 (ja) | 1995-09-11 | 2007-07-18 | 協和醗酵工業株式会社 | ヒトインターロイキン5受容体α鎖に対する抗体 |
WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
EP1500702A1 (en) | 1996-04-01 | 2005-01-26 | Genentech, Inc. | APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy |
WO1999055735A1 (en) | 1998-04-30 | 1999-11-04 | Tanox, Inc. | G-csf receptor agonist antibodies and screening method therefor |
FR2780062B1 (fr) | 1998-06-17 | 2000-07-28 | Rhone Poulenc Rorer Sa | Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations |
CA2371114A1 (en) | 1999-04-22 | 2000-11-02 | Human Genome Sciences, Inc. | Death domain containing receptors |
EP1231937A2 (en) * | 1999-11-19 | 2002-08-21 | Thomas V. Tittle | Tr3-specific binding agents and methods for their use |
US6638906B1 (en) * | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
CA2399388A1 (en) | 2000-02-11 | 2001-08-16 | Michael J. Lenardo | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
AU2002217962A1 (en) | 2000-11-17 | 2002-05-27 | The Burnham Institute | Death domain proteins |
KR100881900B1 (ko) | 2001-04-05 | 2009-02-04 | 가부시키가이샤 멘에키세이부츠 켄큐죠 | 항-오스테오폰틴 항체 및 그 용도 |
DK1578771T3 (da) | 2001-10-10 | 2013-06-10 | Novo Nordisk As | Remodellering og glycokonjugering af peptider |
KR100499989B1 (ko) | 2002-12-27 | 2005-07-07 | 네오바이오다임 주식회사 | 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법 |
US20090317388A1 (en) * | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
CA2621083C (en) | 2005-08-30 | 2017-04-11 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
US20110195048A1 (en) | 2008-10-08 | 2011-08-11 | Podack Eckhard R | Regulation of lymphocytes and uses therefor |
WO2011106707A2 (en) | 2010-02-26 | 2011-09-01 | Human Genome Sciences, Inc. | Antibodies that specifically bind to dr3 |
-
2012
- 2012-03-01 CA CA2828464A patent/CA2828464A1/en not_active Withdrawn
- 2012-03-01 US US13/982,617 patent/US9737612B2/en not_active Expired - Fee Related
- 2012-03-01 BR BR112013022052A patent/BR112013022052A2/pt not_active IP Right Cessation
- 2012-03-01 CN CN201280011136.1A patent/CN103517918A/zh active Pending
- 2012-03-01 EP EP12707996.0A patent/EP2681237A1/en not_active Withdrawn
- 2012-03-01 WO PCT/EP2012/053539 patent/WO2012117067A1/en active Application Filing
- 2012-03-01 RU RU2013141079/10A patent/RU2013141079A/ru unknown
- 2012-03-01 KR KR1020137021269A patent/KR20140043720A/ko not_active Application Discontinuation
- 2012-03-01 MX MX2013009859A patent/MX2013009859A/es unknown
- 2012-03-01 JP JP2013555876A patent/JP6215056B2/ja not_active Expired - Fee Related
-
2013
- 2013-07-18 IL IL227535A patent/IL227535A0/en unknown
- 2013-08-14 ZA ZA2013/06110A patent/ZA201306110B/en unknown
- 2013-08-23 US US13/974,275 patent/US8765130B2/en active Active
-
2014
- 2014-05-01 US US14/267,028 patent/US9713644B2/en not_active Expired - Fee Related
-
2017
- 2017-07-05 US US15/641,611 patent/US20170305994A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9737612B2 (en) | 2017-08-22 |
JP2014509325A (ja) | 2014-04-17 |
RU2013141079A (ru) | 2015-04-10 |
US20140294853A1 (en) | 2014-10-02 |
ZA201306110B (en) | 2014-04-30 |
IL227535A0 (en) | 2013-09-30 |
CA2828464A1 (en) | 2012-09-07 |
US20170305994A1 (en) | 2017-10-26 |
MX2013009859A (es) | 2014-02-28 |
US20130336984A1 (en) | 2013-12-19 |
KR20140043720A (ko) | 2014-04-10 |
JP6215056B2 (ja) | 2017-10-18 |
CN103517918A (zh) | 2014-01-15 |
US8765130B2 (en) | 2014-07-01 |
WO2012117067A1 (en) | 2012-09-07 |
US20130330360A1 (en) | 2013-12-12 |
US9713644B2 (en) | 2017-07-25 |
EP2681237A1 (en) | 2014-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
BR112013022052A2 (pt) | ligantes antagonísticos de dr3 | |
IL284530A (en) | RNAI factors, compositions and methods of using them for the treatment of transthyretin-related diseases | |
EA201891833A1 (ru) | Комбинация для лечения амиотрофического бокового склероза или родственных болезней | |
BR112014011594A2 (pt) | anticorpos anti-il-36r | |
UY33627A (es) | Compuestos para tratar enfermedades neurodegenerativas | |
BR112014009866A2 (pt) | formulações de anticorpos e métodos | |
DK2701697T3 (da) | Oxidative nethindesygdomme | |
MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
BR112015000329A2 (pt) | formulações de diclofenac | |
WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
BR112014005935A2 (pt) | derivados de anilina, sua preparação e sua aplicação terapêutica | |
MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. | |
EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
HK1192726A1 (en) | 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5- | |
EP2861239A4 (en) | TOPICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC SKIN INFLAMMATORY DISEASES | |
BR112013025744A2 (pt) | composicões para tratamento da doença de raynaud | |
BR302012001925S1 (pt) | "configuração aplicada em calota" | |
LV14606A (lv) | Jauns XII faktora inhibitors | |
EA201401045A1 (ru) | Соединения для лечения заболеваний, связанных с ишемией-реперфузией | |
EA201400970A1 (ru) | Новые композиции для лечения амиотрофического бокового склероза | |
BR112015003815A2 (pt) | métodos e composições para o tratamento de uma condição genética | |
TR201106224A2 (tr) | Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler. | |
TH127247B (th) | องค์ประกอบสำหรับการปรับปรุงสภาพของผิวหนัง | |
BR112014027372A2 (pt) | anticorpos anti-il-23p19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A E 5A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |